Placebo to atorvastatin
Sponsors
Organon and Co, Merck Sharp & Dohme LLC, Amgen
Conditions
HypercholesterolemiaHyperlipidemiaPrimary Hyperlipidemia and Mixed DyslipidemiaType 2 Diabetes Mellitus
Phase 3
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)
CompletedNCT01370590
Start: 2011-09-30End: 2012-04-30Updated: 2022-02-09
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)
CompletedNCT01370603
Start: 2011-09-30End: 2012-05-31Updated: 2022-02-09
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
TerminatedNCT01477853
Start: 2011-10-24End: 2012-12-04Updated: 2018-07-26
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3
CompletedNCT01984424
Start: 2013-12-10End: 2017-11-21Updated: 2018-11-29
Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody
CompletedNCT02189837
Start: 2014-07-08End: 2015-03-05Updated: 2018-10-03